Skip to main content
Arvee Laboratories (India) Limited logo

Arvee Laboratories (India) Limited — Investor Relations & Filings

Ticker · ARVEE ISIN · INE006Z01016 LEI · 33580075Q2EAWYCO4C50 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2022-06-27 Board/Management Inform…
Country IN India
Listing National Stock Exchange of India ARVEE

About Arvee Laboratories (India) Limited

http://arveelabs.com/

Arvee Laboratories (India) Limited specializes in the manufacturing and export of specialty chemicals and pharmaceutical intermediates. The company focuses on the production of high-quality chemical compounds, including Dimethyl 5-Sulfoisophthalate Sodium Salt (DMSIP), 5-Sulfoisophthalic Acid Monosodium Salt, and various other aromatic intermediates. These products serve as critical components in the textile, polymer, and pharmaceutical sectors. Arvee Laboratories emphasizes research and development to enhance its chemical synthesis processes and maintain international quality standards. Its operations involve complex chemical reactions such as sulfonation, esterification, and reduction, catering to a diverse global clientele requiring specialized chemical solutions for industrial applications.

Recent filings

Filing Released Lang Actions
General updates
Board/Management Information Classification · 100% confidence The document is a detailed announcement from Arvee Laboratories regarding the outcome of a Board Meeting held on June 27, 2022. It includes approvals for re-appointments of key personnel such as Managing Director, Whole Time Director, Internal Auditors, and Practicing Company Secretaries. It also mentions acceptance of a director's resignation and fixing the date for the Annual General Meeting. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in directors and key managerial personnel. The content focuses on board and management changes rather than financial results, audit reports, or other types of filings. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive disclosure about management changes.
2022-06-27 English
Appointment
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Arvee Laboratories regarding the outcome of a Board Meeting held on June 27, 2022. It includes approvals for re-appointments of key personnel such as the Managing Director, Whole Time Director, Internal Auditors, and Practicing Company Secretaries. It also mentions acceptance of a director's resignation and fixing the date for the Annual General Meeting. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in directors and key managerial personnel. The content focuses on board and management changes rather than financial results, audit opinions, or shareholder voting outcomes. Therefore, this document fits best under the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive disclosure about management changes.
2022-06-27 English
Re-appointment
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Arvee Laboratories regarding the outcome of a Board Meeting held on June 27, 2022. It includes approvals for re-appointments of key personnel such as Managing Director, Whole Time Director, Internal Auditors, and Practicing Company Secretaries. It also mentions acceptance of a director's resignation and fixing the date for the Annual General Meeting. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in directors and key managerial personnel. The content focuses on board and management changes rather than financial results, audit reports, or other report types. Therefore, the document fits the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive disclosure about management changes.
2022-06-27 English
Resignation
Regulatory Filings Classification · 95% confidence The document is a formal notification from Arvee Laboratories (India) Limited to the National Stock Exchange of India regarding the resignation of their statutory auditor. It includes the resignation letter from the auditor, details about the appointment and resignation, reasons for resignation, and compliance with SEBI circular requirements. The content focuses on the auditor's resignation and related disclosures rather than presenting any financial statements, audit opinions, or detailed audit reports. The document length is about 13,184 characters, which is substantial but the content is clearly an announcement of auditor resignation rather than an audit report or annual report. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about auditor resignation and not the audit report itself or a full financial report.
2022-06-18 English
Board Meeting — Other business matters
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 84 characters) and contains no substantive content, financial data, or any report-related information. It appears to be a placeholder or an empty document with no meaningful text. According to the MENU VS MEAL RULE, such a document cannot be classified as a full report but rather falls under a general or fallback category. Since it does not fit any specific filing type, the appropriate classification is Regulatory Filings (RNS).
2022-06-17 English
General updates
Annual Report Classification · 95% confidence The document is a detailed announcement from Arvee Laboratories regarding the outcome of a Board Meeting held on May 26, 2022. It includes approval of audited financial statements for the year ended March 31, 2022, audited financial results, cash flow statement, and auditors' reports. Additionally, it announces the appointment of Mrs. Shalini Jalan as an Independent Director. The document contains substantive financial data such as audited financial results and cash flow statements, as well as management decisions about board appointments. This combination of financial results and board information indicates it is a comprehensive report covering financial performance and management updates. However, since it includes audited financial statements and results for the full fiscal year, it aligns most closely with an Annual Report (10-K equivalent). The presence of board appointment details does not override the primary content of audited financial results. Therefore, the document should be classified as an Annual Report (10-K).
2022-06-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.